<DOC>
	<DOCNO>NCT01923779</DOCNO>
	<brief_summary>Grass pollen allergen recognise major cause allergic disease humans animal . Worldwide , least 40 % allergic patient sensitise grass pollen allergens 50-90 % hayfever seasonal allergy sufferer allergic grass pollen . ToleroMune Grass novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment grass allergy . The purpose optional observational follow-on study evaluate rhinoconjunctivitis symptom exposure Grass EEU among subject complete dose visit study TG002 approximately one year start treatment .</brief_summary>
	<brief_title>ToleroMune Grass Follow Study</brief_title>
	<detailed_description>Subjects complete dose visit post treatment challenge ( PTC ) study TG002 invite attend Screening Visit TG002a . Subjects attend 4 visit EEU successive day . Following last EEC visit follow-up visit perform 3-10 day later .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Previously randomise study TG002 , complete treatment visit PTC calendar year 2012 . `` Partly control '' `` uncontrolled '' asthma History anaphylaxis grass allergen FEV1 &lt; 80 % predict . Treatment betablockers , alphaadrenoreceptor blocker , tranquilizer psychoactive drug Symptoms clinically relevant illness Subjects tolerate allergen challenge EEC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Grass allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Environmental Exposure Unit</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>ToleroMune Grass</keyword>
</DOC>